Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitapivat for Transfusion Burden in Sickle Cell Disease
NCT07656415Phase 3Recruiting
- Sponsor
- Agios Pharmaceuticals
- Start
- Jul 2026
- Primary completion
- Aug 2029
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in sickle cell disease (SCD) comparing Mitapivat with Placebo (2 arms). Primary endpoint: Percentage of Subjects who are Transfusion Free at 52 weeks. Started Jul 2026; status: recruiting.
02
Drugs
mitapivat
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT07656415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07656415.